Literature DB >> 32030290

Local consolidative therapy for oligometastatic non-small cell lung cancer.

Pamela P Samson1,2, Matthew B Spraker1,2, Shahed N Badiyan1,2, Gregory Vlacich1,2, Clifford G Robinson1,2, Aadel A Chaudhuri1,2.   

Abstract

Entities:  

Year:  2019        PMID： 32030290      PMCID： PMC6988032          DOI： 10.21037/jtd.2019.11.19

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  12 in total

Review 1.  A rationale for the targeted treatment of oligometastases with radiotherapy.

Authors:  Dhara M Macdermed; Ralph R Weichselbaum; Joseph K Salama
Journal:  J Surg Oncol       Date:  2008-09-01       Impact factor: 3.454

2.  Oligoprogressive Oncogene-addicted Lung Tumours: Does Stereotactic Body Radiotherapy Have a Role? Introducing the HALT Trial.

Authors:  F McDonald; G G Hanna
Journal:  Clin Oncol (R Coll Radiol)       Date:  2017-11-16       Impact factor: 4.126

3.  Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC).

Authors:  Atif J Khan; Par S Mehta; Thomas W Zusag; Philip D Bonomi; L Penfield Faber; Susan Shott; Ross A Abrams
Journal:  Radiother Oncol       Date:  2006-10-16       Impact factor: 6.280

Review 4.  Oligometastases revisited.

Authors:  Ralph R Weichselbaum; Samuel Hellman
Journal:  Nat Rev Clin Oncol       Date:  2011-03-22       Impact factor: 66.675

5.  Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.

Authors:  David A Palma; Robert Olson; Stephen Harrow; Stewart Gaede; Alexander V Louie; Cornelis Haasbeek; Liam Mulroy; Michael Lock; George B Rodrigues; Brian P Yaremko; Devin Schellenberg; Belal Ahmad; Gwendolyn Griffioen; Sashendra Senthi; Anand Swaminath; Neil Kopek; Mitchell Liu; Karen Moore; Suzanne Currie; Glenn S Bauman; Andrew Warner; Suresh Senan
Journal:  Lancet       Date:  2019-04-11       Impact factor: 79.321

6.  Improving quality of patient care by improving daily practice in radiation oncology.

Authors:  Bhishamjit S Chera; Marianne Jackson; Lukasz M Mazur; Robert Adams; Sha Chang; Kathy Deschesne; Timothy Cullip; Lawrence B Marks
Journal:  Semin Radiat Oncol       Date:  2012-01       Impact factor: 5.934

7.  Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study.

Authors:  Daniel R Gomez; Chad Tang; Jianjun Zhang; George R Blumenschein; Mike Hernandez; J Jack Lee; Rong Ye; David A Palma; Alexander V Louie; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; James W Welsh; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Anne S Tsao; Boris Sepesi; Stephen G Swisher; John V Heymach
Journal:  J Clin Oncol       Date:  2019-05-08       Impact factor: 44.544

8.  Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Authors:  Daniel R Gomez; George R Blumenschein; J Jack Lee; Mike Hernandez; Rong Ye; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Chad Tang; Ritsuko Komaki; Alexander V Louie; David A Palma; Anne S Tsao; Boris Sepesi; William N William; Jianjun Zhang; Qiuling Shi; Xin Shelley Wang; Stephen G Swisher; John V Heymach
Journal:  Lancet Oncol       Date:  2016-10-24       Impact factor: 41.316

9.  Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer.

Authors:  John Conibear; Brendan Chia; Yenting Ngai; Andrew Tom Bates; Nicholas Counsell; Rushil Patel; David Eaton; Corinne Faivre-Finn; John Fenwick; Martin Forster; Gerard G Hanna; Susan Harden; Philip Mayles; Syed Moinuddin; David Landau
Journal:  BMJ Open       Date:  2018-04-17       Impact factor: 2.692

10.  Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial.

Authors:  David A Palma; Robert Olson; Stephen Harrow; Rohann J M Correa; Famke Schneiders; Cornelis J A Haasbeek; George B Rodrigues; Michael Lock; Brian P Yaremko; Glenn S Bauman; Belal Ahmad; Devin Schellenberg; Mitchell Liu; Stewart Gaede; Joanna Laba; Liam Mulroy; Sashendra Senthi; Alexander V Louie; Anand Swaminath; Anthony Chalmers; Andrew Warner; Ben J Slotman; Tanja D de Gruijl; Alison Allan; Suresh Senan
Journal:  BMC Cancer       Date:  2019-08-19       Impact factor: 4.430
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.